Skip to main content
. Author manuscript; available in PMC: 2023 Apr 11.
Published in final edited form as: Mol Pharm. 2019 Dec 31;17(2):404–416. doi: 10.1021/acs.molpharmaceut.9b00644

Figure 2.

Figure 2.

Effects of BDNF (5.71 nmol/kg) + ADTC5 (10 μmol/kg), BDNF alone (5.71 nmol/kg), or vehicle treatments on remyelination in the lateral corpus callosum and surrounding cortex of the brains of SJL/elite EAE mice as stained by Luxol fast blue. (A) Grayscale, the binary conversion, and color photomicrograph of myelin images taken under identical exposure of the lateral corpus callosum of EAE mice treated with BDNF + ADTC5, BDNF alone, or vehicle; the red arrows indicate breakages in the myelin. (B) Quantitative myelin densiometric comparison of white spaces (demyelination) in the brain of BDNF + ADTC5, BDNF alone, and vehicle-treated EAE mice; scale bar = 50 μm; **p ≤ 0.01 ***p ≤ 0.001; one-way ANOVA (95% confidence; n = 5).